AVA6000 is an innovative peptide drug conjugate (PDC) that delivers doxorubicin selectively to tumors with high Fibroblast Activation Protein (FAP) activity, minimizing systemic exposure and reducing side effects.
The ongoing Phase I trial, involving 40 patients with FAP-positive tumors like sarcomas, colorectal, and pancreatic cancers, has demonstrated a favorable safety profile with manageable side effects (e.g., fatigue and alopecia) and rare severe toxicities.
While FAP is prevalent in 50%-80% of prostate cancers, no prostate cancer patients were reported in the trial as of April 2024. But the trial is still recruiting at the moment!
